Definium Therapeutics, Inc. DFTX
$23.74
▲ +2.65% 24H
About
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, specializing in the development of psychedelic-derived therapeutics for psychiatric and neurological disorders. Formerly known as MindMed, it focuses on creating scientifically rigorous treatments that target root cause…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees105
TickerDFTX
Statistics
Market Cap$2.47B
Revenue (TTM)$0
Net Income-$183.8M
Net Margin—
EPS$-2.06
P/E-11.70
P/S—
P/B8.67
EV/EBITDA-14.17
ROE-94.7%
Dividend Yield—
Price$23.74
Data: Twelve Data · Revenue = mcap / P/S